Prognostic value of androgen receptor expression in triple negative breast carcinomas: personal experience and comments on a review about “Triple-negative breast cancer: treatment challenges and solutions” by Collignon et al

Antonio Ieni1 Department of Human Pathology of Adult and Evolutive Age “Gaetano Barresi”, Section of Pathology, University of Messina, AOU “Policlinico G Martino”

Valeria Barresi1 Department of Human Pathology of Adult and Evolutive Age “Gaetano Barresi”, Section of Pathology, University of Messina, AOU “Policlinico G Martino”

Giuseppina Rosaria Rita Ricciardi2 Medical Oncology Unit AOOR Papardo-Piemonte, Department of Human Pathology of Adult And Evolutive Age “Gaetano Barresi”, University of Messina, Messina, Italy

Barbara Adamo3 Medical Oncology Hospital Clinic, Barcelona, Spain

Vincenzo Adamo2 Medical Oncology Unit AOOR Papardo-Piemonte, Department of Human Pathology of Adult And Evolutive Age “Gaetano Barresi”, University of Messina, Messina, Italy

Giovanni Tuccari1 Department of Human Pathology of Adult and Evolutive Age “Gaetano Barresi”, Section of Pathology, University of Messina, AOU “Policlinico G Martino”Correspondence[email protected]

References

CollignonJLousbergLSchroederHJerusalemGTriple-negative breast cancer: treatment challenges and solutionsBreast Cancer: Targets and Therapy2016893107
PubMed Web of Science ®Google Scholar
LehmannBDBauerJAChenXIdentification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesJ Clin Invest201112172750276721633166
PubMed Web of Science ®Google Scholar
GucalpATolaneySIsakoffSJTranslational Breast Cancer Research Consortium (TBCRC 011)Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancerClin Cancer Res201319195505551223965901
PubMed Web of Science ®Google Scholar
RicciardiGRAdamoBIeniAAndrogen receptor (AR), E-cad-herin, and Ki-67 as emerging targets and novel prognostic markers in triple-negative breast cancer (TNBC) patientsPLoS One201536e012836826039245
PubMed Web of Science ®Google Scholar
YuKDZhuRZhanMIdentification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancerClin Cancer Res201319102723273323549873
PubMed Web of Science ®Google Scholar
AnestisAKaramouzisMVDalagiorgouGPapavassiliouAGIs androgen receptor targeting an emerging treatment strategy for triple negative breast cancer?Cancer Treat Rev201541654755325944485
PubMed Web of Science ®Google Scholar

Prognostic value of androgen receptor expression in triple negative breast carcinomas: personal experience and comments on a review about “Triple-negative breast cancer: treatment challenges and solutions” by Collignon et al

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Prognostic value of androgen receptor expression in triple negative breast carcinomas: personal experience and comments on a review about “Triple-negative breast cancer: treatment challenges and solutions” by Collignon et al

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date